IDEXX Laboratories, Inc. Q3 2026 Earnings Call Summary
Published . Updated .
Moby summary of IDEXX Laboratories, Inc.'s Q3 2026 earnings call
Directly affected
- IDXX Idexx Laboratories+4.0% 13d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that IDEXX Laboratories belongs to, so it often moves with news about it.
- LNTH Lantheus Holdings+0.5% 13d
Lantheus Holdings is a peer of IDEXX Laboratories in in vitro and in vivo diagnostic substances; rivals often move on the same news.
- NEOG Neogen-1.2% 30d
Neogen is a peer of IDEXX Laboratories in in vitro and in vivo diagnostic substances; rivals often move on the same news.
- LLY Eli Lilly and+21.6% 30d
Eli Lilly and is a large health company like IDEXX Laboratories; big names in a sector often move together.
- JNJ Johnson & Johnson+1.5% 30d
Johnson & Johnson is a large health company like IDEXX Laboratories; big names in a sector often move together.
- ABBV AbbVie+11.4% 30d
AbbVie is a large health company like IDEXX Laboratories; big names in a sector often move together.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| IDXX | +3.41% | +2.11% | base | +21.10% | after close | after close | after close |
| XLVNo price data for this ticker | — | — | — | — | — | — | — |
| LNTHNo price data for this ticker | — | — | — | — | — | — | — |
| NEOGNo price data for this ticker | — | — | — | — | — | — | — |
| LLYNo price data for this ticker | — | — | — | — | — | — | — |
| JNJNo price data for this ticker | — | — | — | — | — | — | — |
| ABBVNo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
IDEXX Laboratories, Inc. Q3 2026 Earnings Call Summary Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| IDXX | that day | +21.10% | still updating |
| IDXX | three days earlier | +2.11% | final price |
| IDXX | five days earlier | +3.41% | final price |
Congressional trades in the stocks in this story
- Rep. Rohit Khanna bought Idexx Laboratories (IDXX) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 38 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Idexx Laboratories (IDXX) (held by a dependent child), worth $15,001 - $50,000 on 11 Sep 2026. That is 52 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Idexx Laboratories (IDXX) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 59 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 59 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 38 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 55 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 59 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 49 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 59 days before publication. Filed 7 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “IDEXX Laboratories, Inc. Q3 2026 Earnings Call Summary” looks
12 out of 100Price not final
“IDEXX Laboratories, Inc. Q3 2026 Earnings Call Summary” scores 12 out of 100. The score uses 1 sources. The price is not final yet.